Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date31 Dec 2025

Sponsor / Collaborator

Bayer AG

[+1]

NCT07228663

/ Not yet recruitingPhase 3IIT

Rivaroxaban Plus Acetylsalicylic Acid Versus Standard of Care for Arterial and Venous Cardiovascular Prevention After Hip Fracture Surgery in Patients With Myocardial Injury: a Pilot Randomized Trial

A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.

Start Date01 Dec 2025

Sponsor / Collaborator

McMaster University

NCT07246005

/ Not yet recruitingPhase 2

A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2025

Sponsor / Collaborator

Queen Mary University of London

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

9,058

Literatures (Medical) associated with Rivaroxaban

01 Jan 2026·JOURNAL OF ETHNOPHARMACOLOGY

Study on the mechanism of Huoxue Jiedu decoction in the intervention of phosphatidylinositol 3-kinase/serine-threonine kinase/nuclear factor-kappa B pathway in the treatment of deep vein thrombosis

Article

Author: Zhang, Sixiang ; Li, Yuhuan ; Wang, Yingrui ; Liu, Zixuan ; Guo, Bingqi ; Zhao, Youmin ; Liu, Zheng

OBJECTIVE:

This study aimed to investigate the therapeutic effects and underlying molecular mechanisms of HXJDT in the treatment of DVT.

METHODS:

A DVT model was established via the inferior vena cava stenosis method to evaluate the therapeutic effect of HXJDT. Vascular morphology following modeling was examined by hematoxylin-eosin (HE) staining, and the expression differences of M1 and M2 macrophages during thrombus formation were explored by immunohistochemistry. The expression levels of pathway-related proteins and genes were measured using ELISA kits, Western blotting, and quantitative real-time PCR (qPCR).

RESULTS:

This study revealed that the PI3K/Akt/NF-κB signaling pathway was highly expressed in the DVT model. It promoted macrophage recruitment, activated the expression of downstream pro - inflammatory factors (TNF-α, IL-6), upregulated the expression of PAI-1, and downregulated the expression of IL-10 and t-PA, thereby inhibiting thrombus dissolution. PTEN, a negative regulator of the PI3K/Akt/NF-κB pathway, exhibited decreased expression in DVT. Meanwhile, the lncRNA GAS5/miRNA-21 sponge mechanism also played an important role in DVT progression. HXJDT significantly ameliorated the pathogenesis processes of DVT. Notably, the therapeutic effect of high-concentration HXJDT was superior than that of rivaroxaban tablets.

CONCLUSION:

In conclusion, HXJDT regulates the lncRNA GAS5/miRNA-21/PTEN axis to suppress the PI3K/Akt/NF-κB pathway, thereby ameliorating DVT and improving prognosis, which highlights its potential clinical value.

01 Jan 2026·INTERNATIONAL JOURNAL OF CARDIOLOGY

Clinical impact of kidney function in patients with atrial fibrillation receiving oral anticoagulants

Article

Author: Nagashima, Kouichi ; Sakamoto, Daisuke ; Okumura, Yasuo ; Watanabe, Ryuta ; Sotomi, Yohei ; Matsuoka, Yuki ; Sunaga, Akihiro ; Higuchi, Yoshiharu ; Nakatani, Daisaku ; Kanda, Takashi ; Kitamura, Tetsuhisa ; Okada, Katsuki ; Minamiguchi, Hitoshi ; Sakata, Yasushi

BACKGROUND:

Renal function influences the pharmacokinetics of oral anticoagulants in atrial fibrillation (AF), potentially affecting both efficacy and bleeding risk. However, its differential impact across specific agents remains unclear. In this study, we aimed to evaluate the association between renal function and ischemic and bleeding risks in patients with AF, with analyses stratified by anticoagulant type.

METHODS:

We analyzed 7239 patients with non-valvular AF from the DIRECT-Extend registry, a pooled dataset of three large-scale registries. Creatinine clearance (CrCl) was calculated using the Cockcroft-Gault formula and categorized into ≥50, 30 to <50, and 15 to <30 mL/min. The primary ischemic endpoint was stroke or systemic embolism, and the primary bleeding endpoint was major bleeding. Cox proportional hazard models and restricted cubic spline analyses assessed associations between CrCl and outcomes, with subgroup analyses by anticoagulant type.

RESULTS:

Lower CrCl was associated with older age, female sex, and greater comorbidity burden. Impaired renal function was significantly associated with higher ischemic and bleeding risks. Spline analysis demonstrated a continuous increase in both risks with declining CrCl, with a nonlinear relationship for bleeding. Subgroup analyses revealed significant associations between reduced CrCl and ischemic risk in patients on dabigatran, rivaroxaban, edoxaban, and warfarin. Increased bleeding risk was evident for edoxaban and warfarin at lower CrCl levels. No significant association was observed between CrCl and either endpoint in patients receiving apixaban.

CONCLUSION:

In this large real-world cohort, declining renal function was associated with increased ischemic and bleeding risks, highlighting the importance of renal function-based risk assessment in the management of anticoagulation therapy.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Nationwide extrapolation of economic benefit of therapeutic innovation: a 10-year retrospective budget impact of direct oral anticoagulants introduction in France

Article

Author: Belhassen, M. ; Lesage, H. ; Moreau, R. ; Guilmet, C. ; Cotté, F. E. ; Née, M. ; Danchin, N. ; Marant Micallef, C. ; Guitard-Dehoux, D.

OBJECTIVES:

Patients with atrial fibrillation (AF) face increased risks of strokes and systemic thromboembolism (SE), traditionally managed with vitamin K antagonists (VKAs), which are associated with major bleeding (MB) risks. The nationwide real-life data-based NAXOS study, comparing Direct Oral Anticoagulants (DOACs: apixaban, dabigatran, rivaroxaban) to VKAs in over 400,000 AF patients in France, showed that DOACs are more effective, safer, and associated with lower total costs. This study evaluates the 10-year budget impact of DOACs in France, focusing on reductions in strokes/SE, MB, and monitoring costs (INRt).

METHODS:

A retrospective budget impact model from 2014 to 2023 compared scenarios with and without DOACs, using clinical and cost data from the NAXOS study. The target population of DOAC-eligible patients ranged from 725,000 in 2014 to 1.4 million in 2023. Market shares trends were derived from the public national drugs database, indicating that VKAs' use decreased from 67% to 11%, while DOACs, especially apixaban, rose sharply (2% to 55%) over the same period. Costs included treatment acquisition, strokes/SE, MB, and international normalized ratio testing (INRt) for VKAs.

RESULTS:

Over a 10-year horizon, the introduction of DOACs is estimated to have prevented 73,009 strokes, 97,234 major bleeding, and 19,567 stroke-related deaths among patients with NVAF. DOAC introduction increased treatment costs by €5.15 billion over 10 years, and reduced costs for strokes/SE (-€4.24 billion), MB (-€3.22 billion), and INRt (-€1.14 billion), leading to €3.45 billion of savings for National Insurance over 10 years, with apixaban contributing 55% of savings.

LIMITATIONS:

This analysis may not account for all contextual variables, such as indirect costs related to productivity losses.

CONCLUSION:

Over 10 years, the introduction of DOACs in France has generated substantial savings in AF-related costs, highlighting their clinical and economic benefits and the importance for authorities to valorise the external effects of therapeutic innovations.

322

News (Medical) associated with Rivaroxaban

05 Dec 2025

·pipelinereview.com

Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

SAN DIEGO, CA, USA I January 17, 2024 I Tr1X, Inc. today announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases. The financing was led by Bay Area-based The Column Group, with participation from NEVA SGR and Alexandria Ventures. The Company appointed William Lis Chief Executive Officer, strengthened its leadership team with other biopharma industry veterans, and announced members of the Board of Directors and Scientific Advisory Board. "We are thrilled to partner with Bill Lis, Maria Grazia Roncarolo and Tr1X's world-class team to revolutionize the field through its innovative, breakthrough science," said Leon Chen, Ph.D., MBA, Partner at The Column Group and Tr1X Board Member. "With its experienced management team at the helm, we are confident in Tr1X's ability to bring curative cell therapies to patients who currently require life-long treatment and management." Science and Pipeline The Company's science is primarily based on the work of Tr1X's Scientific Founder Maria Grazia Roncarolo, M.D., the discoverer of Type 1 regulatory T (Tr1) cells, which have features that can benefit patients with autoimmune and inflammatory diseases. Tr1 cells, a differentiated subpopulation of regulatory T cells, are crucial for maintaining homeostasis and tolerance in healthy individuals and have several important functions. These include dampening of local inflammation and downregulation of the inflammasome, suppression of pathogenic effector T cell responses, and induction of long-term tolerance as observed in preclinical models and patients. Tr1X's proprietary technology enables the conversion of CD4 + T cells isolated from healthy donors into Treg-like cells that have a similar function and profile to naturally occurring Tr1 cells. These cells can be further engineered to target specific tissues or organs to enable local, targeted immunomodulation. With a proprietary, GMP-grade, closed-loop system that provides consistency, quality and reliability at scale, Tr1X can enable production of its products at commercial volume. Currently, Tr1X is working on its first investigational Tr1 cell therapy, TRX103, which it plans to evaluate in a Phase 1 trial to prevent Graft versus Host Disease (GvHD) in patients undergoing mismatched hematopoietic stem cell transplant. The Company is developing additional pipeline programs to treat inflammatory bowel disease, Type 1 diabetes and multiple B-cell mediated autoimmune diseases. "The ability to develop a pipeline of medicines based on our work on regulatory T cells represents the culmination of decades of discovery and research into the underpinnings of immunological tolerance and autoimmunity," said Dr. Roncarolo, Scientific Founder, President and Head of R&D at Tr1X. "Tr1 cells have unique properties and represent the ideal therapeutic platform from which to develop 'immune reset' products. Our two platforms have the required attributes to address a broad set of indications, including dual targeting of pathogenic T and B cells. These engineered cells have the potential to induce tolerance, which could transform the lives of people living with chronic autoimmune diseases by providing them with a cure instead of ongoing treatment." Proven Leadership Team, Board of Directors and Scientific Advisory Board Tr1X is led by industry veterans with cell therapy expertise who have a track record of discovery, development and commercialization of more than a dozen novel first- or best-in-class medicines. Chief Executive Officer William "Bill" Lis has more than 25 years of biotech executive leadership experience in building companies and product pipelines from R&D stage through commercialization. He most recently served as Chairman and interim CEO of Jasper Therapeutics, Inc., from 2019 to 2022, where he led the company's Series A and follow-on financings and successful brequilimab Phase 1 study readouts in hematopoietic stem cell transplantation. Before that, he served as Chief Executive Officer and a Director of Portola Pharmaceuticals, Inc. from 2008 to 2018 after serving as Chief Operating Officer, where he built the company from a private research-stage startup into a multi-billion dollar public company that launched Andexxa ® and Bevyxxa ® . Portola was acquired by Alexion Pharmaceuticals, Inc. in 2020. Previously, Mr. Lis held executive positions at Scios, Inc. (a Johnson & Johnson company) where he last served as Senior Vice President of New Product Development and Business Development, leading in-licensing efforts, development and commercial P&L operations for Xarelto ® and the company's therapeutics pipeline. Earlier in his career, he held positions at Millennium Pharmaceuticals, Inc., COR Therapeutics, Inc. and Rhone Poulenc Rorer. He is a director of Zai Laboratories, Inc. Scientific Founder, President and Head of R&D Dr. Maria Grazia Roncarolo is the George D. Smith Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and Medicine, Founder of the Center for Definitive and Curative Medicine, and former Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. Dr. Roncarolo has spent her career translating discoveries in immune-mediated diseases and regenerative medicine into novel patient therapies. She and her team were the first to discover Type 1 regulatory T cells in patients and the first to develop curative treatments for ADA-SCID. A pediatric immunologist by training, she was instrumental in bringing novel cell and gene therapies to market, including Strimvelis ® and Libmeldy ® . She is a Co-Founder of the gene-editing companies Graphite Bio and Kamau Therapeutics. Co-Founder and Chief Operating Officer David de Vries has over a decade of experience founding and scaling companies at the intersection of healthcare, biology and technology. Prior to Tr1X, he was Co-Founder and Chief Operating Officer of Arine, a medication intelligence and therapeutic optimization company he helped start, launch and scale to serve millions of patients, working with some of the largest healthcare organizations in the U.S. Previously, he worked at Proteus Digital Health, an innovative drug-device company and the first in the field to obtain FDA approval for a digital medicine, Abilify MyCite ® . "Tr1X is committed to bringing cures to millions of patients suffering from autoimmune diseases through our scalable, universal allogeneic cell therapy process that has been demonstrated to yield billions of cells in a single run," said Mr. Lis, CEO of Tr1X. "In just 18 months, the Tr1X team has successfully closed a Series A financing and extension, assembled an experienced leadership team, board of directors and scientific advisory board, and established a scalable GMP-grade manufacturing process. We are well positioned to advance our pipeline of first-of-their kind allogeneic engineered Treg and CAR-Treg cell therapies that have the potential to address the significant limitations of current cell therapies for autoimmune diseases, which include, among others, poor trafficking, lack of stability, limited persistence and induction of cytokine-associated toxicities, at a fraction of the cost per dose." In addition to Mr. Lis, Dr. Roncarolo and Mr. de Vries, the Tr1X leadership team includes Xavier Paliard, Pharm.D., Ph.D., Chief Scientific Officer; James Adams, MBA, Chief Technical Officer; Jonathan Perrin, J.D., Co-Founder and General Counsel; and Erik Poulsen, M.S., Head of Regulatory Affairs. Joining Mr. Lis and Dr. Roncarolo on Tr1X's Board of Directors are: Tr1X has recruited experts in immunology, stem cell and gene therapy, T-cell biology and immune-mediated diseases to join its Scientific Advisory Board. They include: About Tr1X Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, including the scientists behind the discovery of Tr1 cells, the company's pipeline of universal allogeneic cell therapies is being developed for diseases with high unmet medical need. The company is headquartered in San Diego, has developed a robust intellectual property portfolio, and is backed by leading investors, including The Column Group, NEVA SGR and Alexandria Ventures. For more information visit: www.tr1x.bio . SOURCE: Tr1X

Cell TherapyExecutive ChangePhase 1ImmunotherapyGene TherapyFinancing

24 Nov 2025

·www.fiercebiotech.com

Bayer\'s asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class

Analysts said new data on Bayer’s oral FXIa inhibitor asundexian “provide new confidence that FXIa inhibition can lead to meaningful improvements.\"\n Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past two years.Germany’s Bayer stopped a phase 3 trial of asundexian in patients with atrial fibrillation two years ago after an interim look at the data suggested the molecule was less effective than Bristol Myers Squibb and Pfizer’s Eliquis. Earlier this month, BMS and Johnson & Johnson took a similar action, stopping a phase 3 trial of their rival oral FXIa inhibitor in acute coronary syndrome patients early for futility. Bayer broke the losing streak Sunday, reporting that a phase 3 trial of asundexian for secondary stroke prevention (SSP) met its primary efficacy and safety endpoints. The trial randomized patients who had experienced a non-cardioembolic ischemic stroke or high-risk ischemic attack to receive asundexian or placebo, both in combination with antiplatelet therapy.The risk of stroke was significantly lower on asundexian than on placebo, achieving the study’s primary efficacy endpoint. Asundexian reduced the stroke rate without increasing the risk of major bleeding, the trial’s primary safety endpoint. Bayer plans to talk to regulators in preparation for seeking approval of the drug candidate. Shares in Bayer climbed 10% to 30.28 euros ($34.91) in early trading in Germany. The potential for FXIa inhibitors to stop the formation of clots without raising the risk of bleeding is key to the pitch for the mechanism. Bayer and BMS have bet big on the idea that disentangling thrombosis from hemostasis can match or beat the efficacy of existing drugs while improving the safety profile. Delivering that profile could mitigate the arrival of off-patent rivals to Bayer’s Xarelto and BMS’ Eliquis. Guggenheim analysts said in a note to investors early this month that they had “limited enthusiasm” for Bayer’s stroke readout. But, with Bayer bucking the trend and racking up a phase 3 win, BMO Capital Markets analysts said Sunday that the data “provide new confidence that FXIa inhibition can lead to meaningful improvements in anticoagulation without sacrificing safety risks through increased bleeding.”Bayer is yet to share any numbers from the stroke trial. BMO analysts flagged “the relative contribution of treatment and the degree to which treatment benefit is clinically meaningful” as factors to look out for when Bayer presents the full data. The analysts said Bayer’s data are positive for BMS and J&J’s rival FXIa agent milvexian. While milvexian recently failed one trial, BMS and J&J are continuing to study the asset in SSP and afib. BMS has named afib as the big commercial opportunity. While Bayer has already fallen short in afib, the phase 3 SSP win gives it a shot at sparking growth at a pharma unit that currently has stagnant sales.

$Bayer\'s asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class$

Phase 3

14 Nov 2025

·endpoints.news

Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XI

Pharma’s big quest to make safer blood thinners isn’t going well. On Friday, Bristol Myers Squibb and Johnson & Johnson announced that a Phase 3 trial of their experimental drug milvexian was unlikely to succeed in preventing major heart events such as heart attack or stroke. The companies will discontinue the study. It was expected to enroll 16,000 patients, and is one of three massive trials Bristol Myers and J&J are running for milvexian. The stoppage marks a second such pivotal trial discontinuation for the class of treatments, known as factor XI inhibitors, raising questions as to whether these drugs have a future. In 2023, Bayer stopped its own 14,000-plus-patient study of a factor XI candidate called asundexian in atrial fibrillation after it performed worse than an older drug . But the size of the category continues to draw bets. Big pharma companies believe factor XI inhibitors could be a safer version of current blood thinners like Eliquis and Xarelto — and likewise make tens of billions of dollars. Earlier this year, Novartis bought Anthos Therapeutics for nearly $1 billion upfront, netting a once-monthly factor XI drug it had dropped off with Blackstone six years ago. And this year Regeneron started its own Phase 3 program of a factor XI drug. Milvexian blocks factor XI, a blood clotting protein. Drugmakers have hypothesized that factor XI inhibitors could provide similar benefits as currently available blood thinners, but without the increased risk of bleeds that typically come with them. A Phase 3 trial known as Librexia ACS studied milvexian’s use in patients after a recent episode of acute coronary syndrome, in which blood flow to the heart slows suddenly, likely due to a clot. The trial pitted the experimental pill against placebo, both on top of conventional antiplatelet therapy such as aspirin and other medications. Bristol Myers and J&J decided to discontinue the study after its independent data monitoring committee determined it was not likely to meet its key efficacy endpoint at an interim analysis. But Bristol Myers said that it still had faith in its other two studies, which are looking at milvexian in patients with atrial fibrillation and for use after a stroke. “The Librexia [secondary stroke prevention] and [atrial fibrillation] studies are distinct from Librexia ACS in several aspects, including patient populations, endpoints, type and duration of background therapy and disease pathology,” Roland Chen, Bristol Myers’ head of immunology and cardiovascular drug development, said in a press statement. Data from those studies are expected next year. Shares of Bristol Myers $BMY fell 3% Friday morning, and shares of Bayer dipped nearly 5%.

AcquisitionPhase 3

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thromboembolism	Japan	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	United States	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	European Union	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Iceland	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Liechtenstein	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Norway	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	China	Bayer AG	31 Mar 2009
Myocardial Infarction	Australia	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	Australia	Bayer Australia Ltd.	24 Nov 2008
Stroke	Australia	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	Australia	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	European Union	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Iceland	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Liechtenstein	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Norway	Bayer AG	30 Sep 2008
Embolism	European Union	Bayer AG	30 Sep 2008
Embolism	Iceland	Bayer AG	30 Sep 2008
Embolism	Liechtenstein	Bayer AG	30 Sep 2008
Embolism	Norway	Bayer AG	30 Sep 2008
Peripheral arterial occlusive disease	European Union	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	Australia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Belgium	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Canada	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	France	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Germany	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	India	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Malaysia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Nepal	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Saudi Arabia	Bayer AG	14 Dec 2020
Cardiovascular Diseases	Phase 3	Singapore	Bayer AG	14 Dec 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PREVAPIX-ALL (ASH2025)	Not Applicable	-	19	DOAC	bomvcdjazv(tfzywzlgnl) = oqpqoeemgt mrutwrgxgo (sswbhrmfwq ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Atrial Fibrillation	32,294	Apixaban or Rivaroxaban with Amiodarone	jityuuvxah(wfytjhqwuf) = tmatnwxhec ujbrsqvgeb (jtiptjzwgu )	Positive	06 Dec 2025
				Apixaban or Rivaroxaban with Flecainide or Sotalol	jityuuvxah(wfytjhqwuf) = vcsxlevbuw ujbrsqvgeb (jtiptjzwgu )
NCT02168829 (OCEAN, Pubmed \| N Engl J Med)	Phase 4	Atrial Fibrillation	1,284	Rivaroxaban 15 mg	cdwysvtqau(brxwrrpndy) = slhphirgji wkrpmzrcwg (jomnkkhmac ) View more	Negative	08 Nov 2025
				Aspirin 70-120 mg	cdwysvtqau(brxwrrpndy) = bozfnuigfw wkrpmzrcwg (jomnkkhmac ) View more
NCT02504216 (VOYAGER PAD, Pubmed \| J Am Heart Assoc)	Phase 3	Peripheral Arterial Disease	2,370	Rivaroxaban 2.5 mg	gcugbtnmmm(rlynlopeit): win ratio = 1.16 (95.0% CI, 1.03 - 1.3), P-Value = 0.0167	Positive	04 Nov 2025
				Placebo
NCT06371170 (Pubmed \| Thromb Res)	Not Applicable	-	18	Rivaroxaban	zfejbcaalt(nmelitjhwh) = 67% in warfarin group hxeagzkvlf (lxfmxffogy ) View more	Positive	01 Sep 2025
				Warfarin
NCT04970576 (Pubmed \| JACC Adv)	Phase 4	Thrombosis	261	Rivaroxaban 20 mg daily	vcrsozprvt(heoirwcxnb) = lgvqkkxqob haqmzagtkd (teflfzgcxy ) View more	Positive	01 Aug 2025
				Warfarin (target international normalized ratio 2-3)	vcrsozprvt(heoirwcxnb) = cmlcnvjouf haqmzagtkd (teflfzgcxy ) View more
NCT04755283 (AZALEA-TIMI 71 \| AZALEA-TIMI 71, CTgov)	Phase 2	Stroke \| Atrial Fibrillation	1,287	Abelacimab (Abelacimab 90 mg (MAA868))	coeelevrir = zpobfpqjmr mqbrmcrmqm (nvrauhvvzt, zrbdledcjf - gqespitjkx) View more	-	30 Jul 2025
				Abelacimab (Abelacimab 150 mg (MAA868))	coeelevrir = ynwidqcbfy mqbrmcrmqm (nvrauhvvzt, euvozhijrt - bkythyaczv) View more
PB3023 (EHA2025)	Not Applicable	Multiple Myeloma	101	NOACs (Apixaban 2.5 mg twice daily, Rivaroxaban 10-20 mg per day)	rkievlrtqq(clejymvikq) = Thromboembolic events were observed in only two patients as acute DVTs bbubeeegpt (tlxvsljzmc ) View more	Positive	14 May 2025
NCT02234843 (EINSTEIN-Jr, Pubmed) Manual	Phase 3	Venous Thromboembolism	500	rivaroxaban	jxbmtnuutt(palqemphip) = ltwptluovn bwbrghhrqg (cekytkhvoq ) View more	Positive	01 May 2025
				standard anticoagulants	-
NCT00440193 \| NCT00403767 \| NCT00439777 \| NCT02064439 \| NCT00439725 (ROCKET-AF;EINSTEIN DVT;EINSTEIN PE;EINSTEIN Extension;EINSTEIN CHOICE, Pubmed \| Drugs Aging)	Phase 3	Atrial Fibrillation \| Venous Thromboembolism	-	Rivaroxaban	gjsawtvfsc(zbjpbgrvor) = jfezasncrq naucqvhwew (tbgblmbgic )	Positive	31 Mar 2025
				Placebo	gjsawtvfsc(zbjpbgrvor) = oskkkpcstm naucqvhwew (tbgblmbgic )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis